Abstract:OBJECTIVE:To analyze the differences of clinical manifestations and laboratory features between primary Sjögren's syndrome (pSS) patients with positive and negative anti-Sjögren's syndrome type B (SSB) antibody.METHODS:The clinical data of pSS patients hospitalized in Department of Rheumato-logy and Immunology, Peking University Third Hospital were retrospectively analyzed to investigate the differences of clinical and laboratory features between anti-SSB positive and negative groups. The t test, Mann-Whitney U test, Chi-square test and Fisher's exact probability were used for analysis.RESULTS:A total of 142 pSS patients were enrolled in this study, including 137 females and 5 males with a mean age of (54.8±13.3) years. The anti-SSB positive group included 44 patients accounting for 31.0% of the pSS patients. The anti-SSB positive pSS patients were younger at disease onset and at visit [age at visit: (50.9±14.5) years vs. (56.5±12.4) years; age at onset: (42.2±14.8) years vs. (49.5±15.3) years, P < 0.05]. The patients with anti-SSB positive more frequently presented with rash (29.5% vs. 14.3%, P < 0.05), enlargement of parotid glands (27.3% vs. 8.2%, P < 0.05), renal tubular acidosis (15.9% vs. 4.2%, P < 0.05), immune thrombocytopenia (9.1% vs. 1.0%, P < 0.05), rheumatoid factor (RF) positive (85.0% vs. 49.4%, P < 0.05), higher RF and antinuclear antibody (ANA) titers (median: 89.8 IU/mL vs. 20.5 IU/mL; median: 320 vs. 160, P < 0.05), anti-Sjögren's syndrome type A (SSA) antibody positive (97.7% vs. 64.3%, P < 0.05), elevation of γ globulin (71.4% vs. 38.5%, P < 0.05), higher levels of IgG (median: 21.0 g/L vs. 15.6 g/L, P < 0.05), higher proportions of CD3-CD19+ cells [(21.0±11.9)% vs. (13.7±9.6)%, P < 0.05] and lower proportions of CD3+ cells [(67.2±14.4)% vs. (76.6%±13.1)%, P < 0.05] than those negative. However, the anti-SSB positive group was less likely to show anti-mitochondrial antibodies (AMA)-M2 positivity (10.5% vs. 35.6%, P < 0.05). Glucocorticoids (90.9% vs. 73.5%, P < 0.05) and immunosuppressants (54.5% vs. 36.7%, P < 0.05) were more frequently used in anti-SSB positive pSS patients than those negative.CONCLUSION:The anti-SSB positive pSS patients were younger at disease onset while more frequently presenting with various symptoms, higher levels of other antibodies and activation of B cells than those negative. Glucocorticoids and immunosuppressants were more frequently used, indicating that anti-SSB positive group presented with a more severe clinal phenotype.

Comparative immunohistochemical analysis of inflammatory cytokines in distinct subtypes of Sweet syndrome

Adult-onset immunodeficiency due to anti-interferon-gamma autoantibody-associated Sweet syndrome: A distinctive entity

Insights into the Characteristics of Sweet Syndrome in Patients with and Without Hematologic Malignancy

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Concurrence of Sweet's Syndrome, Pathergy Phenomenon and Erythema Nodosum-Like Lesions.

Positionally distinct interferon stimulated dermal immune acting fibroblasts promote neutrophil recruitment in Sweet's syndrome

Comparison of Cytokine/chemokine Profiles Between Dermatomyositis and Anti-Synthetase Syndrome

Serum cytokine profile in pediatric Sweet's syndrome: a case report

[Comparison of Clinical and Immunological Characteristics Between Primary Sjögren's Syndrome Patients with Positive and Negative Anti-Ssb Antibody].

Distinctive profile of monomeric and polymeric anti-SSA/Ro52 immunoglobulin A1 isoforms in saliva of patients with primary Sjögrens syndrome and Sicca

Distinctive Profile of Monomeric and Polymeric Anti-Ssa/ro52 Immunoglobulin A1 Isoforms in Saliva of Patients with Primary Sjögren’s Syndrome and Sicca

Clinical stratification of 1318 Primary Sjögren's Syndrome patients

Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome

Gender Differences in Clinical and Immunological Characteristics and the Pathogenic Study of Primary Sj(o)gren's Syndrome

Atypical Sweet syndrome: skin sinus tracts in an acutely febrile patient after lymphoma treatment: a case report

Subcutaneous Sweet Syndrome With Vasculitis Features: Case Report and Review

+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications

Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis

Intracranial infection accompanied sweet's syndrome in a patient with anti-interferon-γ autoantibodies: A case report

Histological differences related to autophagy in the minor salivary gland between primary and secondary types of Sjögren's syndrome

Clinical characteristics, diagnosis and management of Sweet syndrome induced by azathioprine